CARGO Therapeutics, Inc.
cargo-tx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 6, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 14, 2025.
10-Q for Q2 FY2025, filed Aug 6, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops engineered immune-cell therapies for cancer patients, including a candidate for B-cell cancers and an off-the-shelf cell-therapy platform.
10-K for FY2024, filed Mar 12, 2025
How Did They Make Money?
No revenue was reported.
10-K for FY2024, filed Mar 12, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 6, 2025
−$49.9MView ↗
- ▲ +13% (Loss)
- vs −$44.3M in Q2 FY2024
-
Aug 19, 2025
Concentra completed its acquisition of CARGO
CARGO became a wholly owned subsidiary of Concentra.
Sources
8-K, filed Aug 19, 2025
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on August 18, 2025, Parent completed a tender…View ↗
-
Jul 8, 2025
CARGO agreed to be acquired by Concentra
The deal offered $4.379 in cash per share plus one contingent value right.
Sources
8-K, filed Jul 8, 2025
On July 7, 2025, CARGO Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the…View ↗
-
Mar 18, 2025
CARGO suspended pipeline development and appointed an interim CEO
Anup Radhakrishnan was appointed to lead the company through a reverse merger or other business combination.
Sources
8-K, filed Mar 18, 2025
On March 13, 2025, the Board of Directors (the “Board”) of CARGO Therapeutics, Inc. (the “Company” or “CARGO”) approved a further reduction…View ↗
Who Did They Compete With?
Competes with AbelZeta Pharma, Autolus Therapeutics, Galapagos, Gilead Sciences, Janssen Biotech, Legend Biotech, Lyell Immunopharma, Marker Therapeutics, Miltenyi Biotec, Novartis International, Regeneron Pharmaceuticals, Allogene Therapeutics, AstraZeneca, Atara Biotherapeutics, Beam Therapeutics, Caribou Biosciences, Cellectis, Century Therapeutics, CRISPR Therapeutics, and Editas Medicine
10-K for FY2024, filed Mar 12, 2025Due to the promising therapeutic effect of CAR T-cell therapies in clinical trials, we anticipate increasing competition from existing and…View ↗
Loading...
